Coagulation abnormalities and thrombosis in patients with COVID-19

Lancet Haematol. 2020 Jun;7(6):e438-e440. doi: 10.1016/S2352-3026(20)30145-9. Epub 2020 May 11.

Authors

Marcel Levi¹, Jecko Thachil², Toshiaki Iba³, Jerrold H Levy⁴

Affiliations

¹ Cardiometabolic Programme, National Institute for Health Research University College London Hospitals (UCLH) Biomedical Research Centre, London, UK; Department of Medicine, UCLH National Health Service Foundation Trust, London, NW1 2PG, UK. Electronic address: marcel.levi@nhs.net.
² Department of Haematology, Manchester Royal Infirmary, Manchester, UK.
³ Department of Emergency and Disaster Medicine, Jutendo University Graduate School of Medicine, Tokyo, Japan.
⁴ Department of Anesthesiology, Critical Care, and Surgery, Duke University School of Medicine, Durham, NC, USA.

No abstract available

MeSH terms

Anticoagulants / therapeutic use
Betacoronavirus / isolation & purification
Blood Coagulation* / drug effects
COVID-19
Coronavirus Infections / blood*
Coronavirus Infections / complications
Disseminated Intravascular Coagulation / blood*
Disseminated Intravascular Coagulation / complications
Disseminated Intravascular Coagulation / drug therapy
Fibrin Fibrinogen Degradation Products / analysis
Heparin, Low-Molecular-Weight / therapeutic use
Humans
Pandemics
Platelet Count
Pneumonia, Viral / blood*
Pneumonia, Viral / complications
Prothrombin Time
SARS-CoV-2
Thrombosis / blood*
Thrombosis / complications
Thrombosis / drug therapy

Substances

Anticoagulants
Fibrin Fibrinogen Degradation Products
Heparin, Low-Molecular-Weight
fibrin fragment D

Associated data

ClinicalTrials.gov/NCT04372589
ClinicalTrials.gov/NCT04367831
ClinicalTrials.gov/NCT04345848
ClinicalTrials.gov/NCT04366960